BioAdvance News

TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma

By WebmasterNovember 18, 2008November 1st, 2024No Comments

TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma
Read more here

Previous PostQR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease
Next PostJenrin Discovery’s Non-Brain Penetrant Cb1 Antagonists Show Beneficial Effects in Treating Diabetes and Obesity